The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology.

Autor:	Virani SS; Baylor College of Medicine, Houston, Texas, USA (Drs Virani, Ballantyne); Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA (Dr Virani); The Aga Khan University, Karachi, Pakistan (Dr Virani)., Aspry K; Lifespan Cardiovascular Institute, and Alpert Medical School, Brown University, Providence, Rhode Island, USA (Dr Aspry)., Dixon DL; Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA (Dr Dixon)., Ferdinand KC; Tulane University School of Medicine, New Orleans, Louisiana, USA (Dr Ferdinand)., Heidenreich PA; Stanford University, Palo Alto, California, USA (Dr Heidenreich)., Jackson EJ; CardioTexas, Austin, Texas, USA (Ms Jackson)., Jacobson TA; Emory University School of Medicine, Atlanta, Georgia, USA (Dr Jacobson)., McAlister JL; Piedmont Heart Institute, Atlanta, Georgia, USA (Dr McAlister)., Neff DR; Michigan State University, College of Osteopathic Medicine, Department of Family and Community Medicine, East Lansing, Michigan, USA (Dr Neff)., Gulati M; Smidt Cedars-Sinai Heart Institute, Los Angeles, California, USA (Dr Gulati)., Ballantyne CM; Baylor College of Medicine, Houston, Texas, USA (Drs Virani, Ballantyne). Electronic address: cmb@bcm.edu.
Jazyk:	angličtina
Zdroj:	Journal of clinical lipidology [J Clin Lipidol] 2023 Mar-Apr; Vol. 17 (2), pp. 208-218. Date of Electronic Publication: 2023 Feb 27.
DOI:	10.1016/j.jacl.2023.02.003
Abstrakt:	Despite the established role of low-density lipoprotein cholesterol (LDL-C) as a major risk factor for cardiovascular disease (CVD), and the persistence of CVD as the leading cause of morbidity and mortality in the United States, national quality assurance metrics no longer include LDL-C measurement as a required performance metric. This clinical perspective reviews the history of LDL-C as a quality and performance metric and the events that led to its replacement. It also presents patient, healthcare provider, and health system rationales for re-establishing LDL-C measurement as a performance measure to improve cholesterol control in high-risk groups and to stem the rising tide of CVD morbidity and mortality, cardiovascular care disparities, and related healthcare costs. (Copyright © 2023. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Full Text from ScienceDirect